These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 6696702)

  • 21. Treatment of severe motion sickness with antimotion sickness drug injections.
    Graybiel A; Lackner JR
    Aviat Space Environ Med; 1987 Aug; 58(8):773-6. PubMed ID: 3632537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of effectiveness of some antimotion sickness drugs using recommended and larger than recommended doses as tested in the slow rotation room. NSAM-945.
    Wood CD; Graybiel A; Kennedy RS
    Res Rep U S Nav Sch Aviat Med; 1965 Jul; ():1-9. PubMed ID: 5322559
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of drug countermeasures for space motion sickness on working memory in humans.
    Paule MG; Chelonis JJ; Blake DJ; Dornhoffer JL
    Neurotoxicol Teratol; 2004; 26(6):825-37. PubMed ID: 15451046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prokinetic effects of erythromycin after antimotion sickness drugs.
    Stewart JJ; Wood MJ; Parish RC; Wood CD
    J Clin Pharmacol; 2000 Apr; 40(4):347-53. PubMed ID: 10761161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of antimotion sickness drugs: a new effective remedy revealed.
    Wood CD; Graybiel A
    Aerosp Med; 1970 Aug; 41(8):932-3. PubMed ID: 4988606
    [No Abstract]   [Full Text] [Related]  

  • 26. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectivity of antimotion sickness drugs during artificial gravity simulations.
    Green JA
    Aerosp Med; 1973 Nov; 44(11):1255-60. PubMed ID: 4586812
    [No Abstract]   [Full Text] [Related]  

  • 28. Side effects of some antimotion sickness drugs as measured by psychomotor test and questionnaires.
    Kennedy RE; Wood CD; Graybiel A; McDonough RB
    Aerosp Med; 1966 Apr; 37(4):408-11. PubMed ID: 5954449
    [No Abstract]   [Full Text] [Related]  

  • 29. Promethazine, scopolamine and cinnarizine: comparative time course of psychological performance effects.
    Parrott AC; Wesnes K
    Psychopharmacology (Berl); 1987; 92(4):513-9. PubMed ID: 3114803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and duration of intramuscular antimotion sickness medications.
    Wood CD; Stewart JJ; Wood MJ; Mims M
    J Clin Pharmacol; 1992 Nov; 32(11):1008-12. PubMed ID: 1474161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of motion sickness and antimotion sickness drugs on gastric function.
    Stewart JJ; Wood MJ; Wood CD; Mims ME
    J Clin Pharmacol; 1994 Jun; 34(6):635-43. PubMed ID: 8083395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of transcutaneous scopolamine and depth on diver performance.
    Williams TH; Wilkinson AR; Davis FM; Frampton CM
    Undersea Biomed Res; 1988 Mar; 15(2):89-98. PubMed ID: 3363755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacologic agents for preventing and treating motion sickness].
    Shashkov VS; Sabaev VV
    Kosm Biol Aviakosm Med; 1981; 15(1):9-18. PubMed ID: 6111621
    [No Abstract]   [Full Text] [Related]  

  • 34. [A new approach to the search for vestibuloprotectors].
    Yasnetsov VV; Karsanova SK; Yasnetsov VV
    Aviakosm Ekolog Med; 2015; 49(1):5-12. PubMed ID: 25958460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Various anti-motion sickness drugs and core body temperature changes.
    Cheung B; Nakashima AM; Hofer KD
    Aviat Space Environ Med; 2011 Apr; 82(4):409-15. PubMed ID: 21485398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Motion sickness in cats: a symptom rating scale used in laboratory and flight tests.
    Suri KB; Crampton GH; Daunton NG
    Aviat Space Environ Med; 1979 Jun; 50(6):614-8. PubMed ID: 475712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computerized task battery assessment of cognitive and performance effects of acute phenytoin motion sickness therapy.
    Chelen W; Ahmed N; Kabrisky M; Rogers S
    Aviat Space Environ Med; 1993 Mar; 64(3 Pt 1):201-5. PubMed ID: 8447800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.